crgd-zw800-1
Small moleculeexperimentalImaging agent
Clinical trial activity
4 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Jan 31, 2020 (NCT04191460)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Loading structure…
SMILES
CC1(C)C(C=CC2=C(Oc3ccc(CCC(=O)O)cc3)C(=CC=C3N(CCC[N+](C)(C)C)c4ccc(S(=O)(=O)[O-])cc4C3(C)C)CCC2)=[N+](CCC[N+](C)(C)C)c2ccc(S(=O)(=O)[O-])cc21.O=C([O-])C(F)(F)F- Mol. weight
- 1057.26 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068515 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06101745 | Phase 2/Phase 3 (Phase 3) | Jan 31, 2024 | Cedars-Sinai Medical Center, Erasmus University Rotterdam, Isala Clinics, Zwolle, The Netherlands, Leiden University, Stanford University, University of Groningen, University of Massachusetts |
| NCT05752149 | Phase 2 | May 31, 2023 | Erasmus University Rotterdam |
| NCT05518071 | Phase 2 | Nov 9, 2022 | Leiden University |
| NCT04191460 | Phase 2 | Jan 31, 2020 | Erasmus University Rotterdam |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Erasmus University Rotterdam | Academic/Hospital | 3 | 2 | 2 | 2020 |
| Leiden University | Academic/Hospital | 2 | 1 | 2 | 2022 |
| Cedars-Sinai Medical Center | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Isala Clinics, Zwolle, The Netherlands | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Stanford University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| University of Groningen | Academic/Hospital | 1 | 0 | 1 | 2024 |
| University of Massachusetts | Academic/Hospital | 1 | 0 | 1 | 2024 |
7 organizations
Page 1 / 1